ScholarIQanswers from OpenAlex & ORCID
Ravinder N. Maini
ResearcherPublications, citations & collaboration network
Ravinder N. Maini is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Ravinder N. Maini have?
ScholarIQindexed works
Ravinder N. Maini has 337 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ravinder N. Maini have?
ScholarIQcitation count
Ravinder N. Maini has 40,533 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Ravinder N. Maini?
ScholarIQh-index
Ravinder N. Maini has an h-index of 86 in OpenAlex.
What is the i10-index of Ravinder N. Maini?
ScholarIQi10-index
Ravinder N. Maini has an i10-index of 206 in OpenAlex.
What is the OpenAlex record for Ravinder N. Maini?
ScholarIQopenalex
The OpenAlex for Ravinder N. Maini is on the source record.
What are the most-cited papers on Ravinder N. Maini?
ScholarIQmost cited works
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Peter E. Lipsky, Désirée van der Heijde, E. William St. Clair, Daniel E. Fürst, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S Smolen, Michael H. Weisman, Paul Emery, Marc Feldmann, Gregory R. Harriman, Ravinder N. Maini
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
Ravinder N. Maini, E. William St. Clair, Ferdinand C. Breedveld, Daniel E. Fürst, Joachim R. Kalden, Michael H. Weisman, Josef S. Smolen, Paul Emery, Gregory R. Harriman, Marc Feldmann, Peter E. Lipsky
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
Michael J. Elliott, Ravinder N. Maini, Marc Feldmann, Joachim R. Kalden, Christian Antoni, Josef S Smolen, Burkhard F. Leeb, F. C. Breedveld, J. D. Macfarlane, J. A. Bijl, James N. Woody
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor ? monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
Ravinder N. Maini, Ferdinand C. Breedveld, Joachim R. Kalden, Josef S Smolen, Diana Davis, J. D. Macfarlane, Christian Antoni, Burkhard F. Leeb, Michael J. Elliott, James N. Woody, T Schaible, Marc Feldmann
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European community
Claudio Vitali, Stefano Bombardieri, Haralampos Μ. Moutsopoulos, G. Balestrieri, W. Bencivelli, Robert M. Bernstein, K. Bjerrum, S. Braga, Joaquı́n Coll, Salvatore De Vita, Alexandros A. Drosos, Michael Ehrenfeld, P.Y. Hatron, Elaine M. Hay, David Isenberg, Anne Janin, Joachim R. Kalden, L Kater, Yrjö T. Konttinen, Peter J. Maddison, Ravinder N. Maini, R. Manthorpe, Olivier Meyer, Pierantonio Ostuni, Yvon Pennec, Jan Ulrik Prause, Andrea Richards, B Sauvezie, Morten Schiødt, Maria Elisa Sciuto, Crispian Scully, Yehuda Shoenfeld, Fotini N. Skopouli, Josef S Smolen, M L Snaith, Moshe Tishler, S Todesco, Guido Valesini, Patrick J Venables, Marie J. Wattiaux, Pierre Youinou